Emergent repurchases debt. Emergent BioSolutions stock sits 54.69 percent below its high

Published on 10/02/2026 at 04:04 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Emergent repurchased USD 75 million of notes on September 3, 2026. Emergent BioSolutions stock sits 54.69 percent below its USD 14.06 high.

EBS, US29089Q1058, Illustration mit AI erstellt.

Emergent BioSolutions (ISIN US29089Q1058) was last quoted at USD 6.37 on the NYSE on October 1, 2026 at 4:00 p.m. ET after hours, 54.69 percent below its USD 14.06 52-week high. The company completed a USD 75 million repurchase of senior unsecured notes on September 3, 2026, according to Emergent BioSolutions.

Debt reduction strengthens the balance sheet

The debt transaction is part of a broader turnaround. At the September 14, 2026 H.C. Wainwright conference, management said gross debt had fallen to USD 515 million after an additional USD 75 million payment, compared with USD 800 million at the end of 2023 and early 2024, according to Investing.com.

The same presentation put net leverage at roughly two times and said a USD 50 million share-repurchase authorization runs through March 2027. The balance-sheet progress gives the company more room to invest in its medical-countermeasures portfolio while managing refinancing needs.

Revenue growth meets competitive pressure

Emergent reported USD 390 million of year-to-date revenue for the first half of 2026, an increase of USD 27 million from the prior-year period. Adjusted EBITDA rose to USD 132 million from USD 112 million, while adjusted EBITDA margin expanded by 3 percentage points, according to Investing.com.

Medical countermeasures revenue reached USD 168 million in the second quarter of 2026, the highest second-quarter figure since 2020. The countermeasure business is therefore the clearest growth engine, but management also described pricing pressure in NARCAN as four generic rivals compete in the naloxone market.

Analyst target remains above the quote

HC Wainwright reaffirmed its Buy rating and maintained a USD 10.00 price target on September 9, 2026, according to MarketBeat. That target is 57.00 percent above the latest USD 6.37 primary-market quote, while the stock remains 54.69 percent below its USD 14.06 52-week high.

Prior close sets the euro reference

The prior close at Lang & Schwarz was EUR 5.72 on September 30, 2026. Emergent BioSolutions remains a Healthcare company in the specialty and generic drug-manufacturing industry, with a market capitalization of USD 328.7 million as of October 1, 2026.